CN111000976A - 一种预防白内障胶囊及其制备方法 - Google Patents
一种预防白内障胶囊及其制备方法 Download PDFInfo
- Publication number
- CN111000976A CN111000976A CN202010012314.9A CN202010012314A CN111000976A CN 111000976 A CN111000976 A CN 111000976A CN 202010012314 A CN202010012314 A CN 202010012314A CN 111000976 A CN111000976 A CN 111000976A
- Authority
- CN
- China
- Prior art keywords
- extract
- capsule
- vitamin
- cataract
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 40
- 239000002775 capsule Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 38
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 108010024636 Glutathione Proteins 0.000 claims abstract description 20
- 235000019198 oils Nutrition 0.000 claims abstract description 20
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241001523681 Dendrobium Species 0.000 claims abstract description 19
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 19
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 19
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 19
- 235000005473 carotenes Nutrition 0.000 claims abstract description 19
- 150000001746 carotenes Chemical class 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 19
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 19
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 19
- 229940046009 vitamin E Drugs 0.000 claims abstract description 19
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 19
- 239000011709 vitamin E Substances 0.000 claims abstract description 19
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 19
- 239000011701 zinc Substances 0.000 claims abstract description 19
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 19
- 235000016804 zinc Nutrition 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 18
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 18
- 229960003180 glutathione Drugs 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 13
- 230000002829 reductive effect Effects 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000011259 mixed solution Substances 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 208000030533 eye disease Diseases 0.000 abstract description 5
- 208000003464 asthenopia Diseases 0.000 abstract description 4
- 230000004438 eyesight Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 239000005445 natural material Substances 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 240000004638 Dendrobium nobile Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- 102000014824 Crystallins Human genes 0.000 description 2
- 108010064003 Crystallins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004297 night vision Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种预防白内障胶囊及其制备方法，该预防白内障胶囊按重量百分比计由以下原料制得：5～6％石斛提取物、2～3％还原性谷胱甘肽、5～6％胡萝卜素、2～4％蓝莓提取物、2～4％葡萄籽提取物、0.5～1％乙酰半胱氨酸、1～1.2％维生素E、1～1.2％维生素C、0.2～0.5％锌、30～40％葵花籽油；剩余为水。通过将上述重量百分比的原料进行分批混合、加热搅拌和制粒，制得该预防白内障胶囊。本发明采用“药食同源”的石斛作为原料，辅以其他天然物质进行复配，制得一种胶囊，对于白内障等眼部疾病的预防十分有效，此外还可以消除眼睛疲劳，增加视力，提高免疫力，市场前景十分可观。
Description
技术领域
本发明属于预防白内障领域，具体涉及一种预防白内障胶囊及其制备方法。
背景技术
随着社会经济的不断发展，人们的生活节奏越来越快，每天使用电脑和手机的时间不断增加，这对于眼睛来说是很大的负担，容易造成眼疲劳引发各种眼部疾病，而白内障就是潜在风险之一。
白内障分为先天性白内障和后天性白内障，而大部分后天性白内障都是由于营养问题和用眼习惯造成的，除了呼吁养成良好的用眼习惯之外，现在也存在很多关于预防白内障的措施，包括物理结构上的产品和作用于人体的药品，而物理结构上的产品大都存在价格高、携带不方便的问题；而对于药品来说，人们都明白滥用药物并不是一个好的选择，随着人们消费观念的转变，“食疗为主，药疗为辅”渐渐变为大众挑选食品的首要考虑问题，因此，提出一种食药同源、能够有效预防白内障等眼部疾病的保健品将十分受欢迎。
发明内容
本发明的目的是为了提供一种食药同源、能够有效预防白内障等眼部疾病的胶囊，具体通过以下技术方案实现：
一种预防白内障胶囊，按重量百分比计由以下原料制得：5～6％石斛提取物、2～3％还原性谷胱甘肽、5～6％胡萝卜素、2～4％蓝莓提取物、2～4％葡萄籽提取物、0.5～1％乙酰半胱氨酸、1～1.2％维生素E、1～1.2％维生素C、0.2～0.5％锌、30～40％葵花籽油；剩余为水。
本发明以石斛提取物、还原性谷胱甘肽和葡萄籽提取物作为原料之三，对于预防白内障有很好的作用效果。其中，石斛是一种药用植物，是中医“治未病”最重要的一种药物之一，现代医学证明，石斛可以促进血液循环，提高人体免疫力，对眼科疾病有明显的治疗作用，对半乳糖性白内障不仅有抑制作用，而且有一定的治疗作用；能够全面修复血管，神经等系统病变；消除视力模糊等症状。而还原型谷胱甘肽是一种作用广泛的生理因子，它是由谷氨酸、半胱氨酸及甘氨酸组成的一种三肽，广泛分布于机体各器官内，在维持细胞生理功能方面起着重要的作用；研究发现，还原型谷胱甘肽对不稳定的眼晶状体蛋白质巯基有抑制作用，从而能够抑制白内障的发展，抑制角膜及视网膜病变，在角膜损害时能促进上皮组织的修复。葡萄籽提取物能够有效预防和减轻紫外线辐射对眼睛及皮肤的伤害，防治红血丝，增强夜视力、减少视网膜症等，阻止自由基对晶状体蛋白的氧化，预防白内障、视网膜炎，是目前自然界中发现的抗氧化、清除自由基能力最强的物质，能有效清除人体内多余的自由基，具有超强的延缓衰老和增强免疫力的作用。
此外，本发明还添加有胡萝卜素、蓝莓提取物、乙酰半胱氨酸、维生素E、维生素C和锌。胡萝卜素是一种具有生理活性的物质，在动物体内可转化成维生素A，可治疗夜盲症，干眼病及上皮组织角化症；蓝莓可以消除眼睛疲劳，增加视力；而且具有降低胆固醇、抑制脂蛋白氧化、抗氧化、抗衰老和抗炎等功能，其中的花青素还可促进视网膜细胞中视紫质的再生成，而视紫质正是保证良好视力不可或缺的成分。而维生素E能够抑制眼睛晶状体内的过氧化脂反应，使末梢血管扩张，改善血液循环。乙酰半胱氨酸能够预防角膜炎、结膜炎。微量元素锌能够产生黑色素保护眼睛健康，提高夜视能力，预防黄斑区变异。
按照一定比例将上述的天然成分进行复配，制成本发明的胶囊，至少在预防白内障的方面具有很好的效果，改善白内障越来越低龄化的趋势。
在一些优选的实施情况中，上述的预防白内障胶囊按重量百分比计由以下原料制得：6％石斛提取物、2％还原性谷胱甘肽、5％胡萝卜素、3％蓝莓提取物、3％葡萄籽提取物、0.8％乙酰半胱氨酸、1.1％维生素E、1.1％维生素C、0.4％锌、35％葵花籽油；剩余为水。
在一些优选的实施情况中，上述的预防白内障胶囊按重量百分比计由以下原料制得：5％石斛提取物、3％还原性谷胱甘肽、6％胡萝卜素、2％蓝莓提取物、4％葡萄籽提取物、1％乙酰半胱氨酸、1％维生素E、1％维生素C、0.5％锌、38％葵花籽油；剩余为水。
在一些优选的实施情况中，上述的预防白内障胶囊按重量百分比计由以下原料制得：6％石斛提取物、3％还原性谷胱甘肽、5％胡萝卜素、4％蓝莓提取物、2％葡萄籽提取物、0.6％乙酰半胱氨酸、1.2％维生素E、1.2％维生素C、0.3％锌、32％葵花籽油；剩余为水。
本发明还提供了一种上述预防白内障胶囊的制备方法，具体过程如下：
S1：将质量百分比的维生素E、维生素C、胡萝卜素、葵花籽油、水进行混合，在50～60℃的条件下搅拌15～20min，得到混合液A；
S2：将质量百分比的石斛提取物、还原性谷胱甘肽、蓝莓提取物、葡萄籽提取物、乙酰半胱氨酸、锌加入至混合液A中，然后在50～60℃的条件下继续搅拌30～60min，得到混合液B；
S3：将混合液B冷却至25～35℃，然后加入至软胶囊制粒机，制成所述预防白内障胶囊。
在一些优选的实施情况中，S2中，搅拌的时间为45～50min；S3中，将混合液C冷却至29～31℃。
有益效果：本发明采用“药食同源”的石斛作为原料，辅以其他天然物质进行复配，制得一种胶囊，对于白内障等眼部疾病的预防十分有效，此外还可以消除眼睛疲劳，增加视力，提高免疫力，市场前景十分可观。
具体实施方式
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整的描述，以充分地理解本发明的目的、方案和效果。需要说明的是，在不冲突的情况下，本申请中的实施例及实施例中的特征可以相互组合。
实施例1：
一种预防白内障胶囊，按重量百分比计由以下原料制得：6％石斛提取物、2％还原性谷胱甘肽、5％胡萝卜素、3％蓝莓提取物、3％葡萄籽提取物、0.8％乙酰半胱氨酸、1.1％维生素E、1.1％维生素C、0.4％锌、35％葵花籽油；剩余为水。制备该预防白内障胶囊的具体过程如下：
S1：将质量百分比的维生素E、维生素C、胡萝卜素、葵花籽油、水加入至反应釜中混合，在50～60℃的条件下搅拌15～20min，得到混合液A；
S2：将质量百分比的石斛提取物、还原性谷胱甘肽、蓝莓提取物、葡萄籽提取物、乙酰半胱氨酸、锌加入至反应釜中，然后在50～60℃的条件下继续搅拌45～50min，得到混合液B；
S3：将混合液B冷却至29～31℃，采用膜超滤器滤去混合油中的微粒及细菌，然后加入至自动软胶囊制粒机，制成该预防白内障胶囊。
实施例2：
一种预防白内障胶囊，按重量百分比计由以下原料制得：5％石斛提取物、3％还原性谷胱甘肽、6％胡萝卜素、2％蓝莓提取物、4％葡萄籽提取物、1％乙酰半胱氨酸、1％维生素E、1％维生素C、0.5％锌、38％葵花籽油；剩余为水。制备该预防白内障胶囊的具体过程如下：
S1：将质量百分比的维生素E、维生素C、胡萝卜素、葵花籽油、水加入至反应釜中混合，在50～60℃的条件下搅拌15～20min，得到混合液A；
S2：将质量百分比的石斛提取物、还原性谷胱甘肽、蓝莓提取物、葡萄籽提取物、乙酰半胱氨酸、锌加入至反应釜中，然后在50～60℃的条件下继续搅拌45～50min，得到混合液B；
S3：将混合液B冷却至29～31℃，采用膜超滤器滤去混合油中的微粒及细菌，然后加入至自动软胶囊制粒机，制成该预防白内障胶囊。
实施例3：
一种预防白内障胶囊，按重量百分比计由以下原料制得：6％石斛提取物、3％还原性谷胱甘肽、5％胡萝卜素、4％蓝莓提取物、2％葡萄籽提取物、0.6％乙酰半胱氨酸、1.2％维生素E、1.2％维生素C、0.3％锌、32％葵花籽油；剩余为水。制备该预防白内障胶囊的具体过程如下：
S1：将质量百分比的维生素E、维生素C、胡萝卜素、葵花籽油、水加入至反应釜中混合，在50～60℃的条件下搅拌15～20min，得到混合液A；
S2：将质量百分比的石斛提取物、还原性谷胱甘肽、蓝莓提取物、葡萄籽提取物、乙酰半胱氨酸、锌加入至反应釜中，然后在50～60℃的条件下继续搅拌45～50min，得到混合液B；
S3：将混合液B冷却至29～31℃，采用膜超滤器滤去混合油中的微粒及细菌，然后加入至自动软胶囊制粒机，制成该预防白内障胶囊。
Claims (7)
1.一种预防白内障胶囊，其特征在于，按重量百分比计由以下原料制得：5～6％石斛提取物、2～3％还原性谷胱甘肽、5～6％胡萝卜素、2～4％蓝莓提取物、2～4％葡萄籽提取物、0.5～1％乙酰半胱氨酸、1～1.2％维生素E、1～1.2％维生素C、0.2～0.5％锌、30～40％葵花籽油；剩余为水。
2.根据权利要求1所述的预防白内障胶囊，其特征在于，按重量百分比计由以下原料制得：6％石斛提取物、2％还原性谷胱甘肽、5％胡萝卜素、3％蓝莓提取物、3％葡萄籽提取物、0.8％乙酰半胱氨酸、1.1％维生素E、1.1％维生素C、0.4％锌、35％葵花籽油；剩余为水。
3.根据权利要求1所述的预防白内障胶囊，其特征在于，按重量百分比计由以下原料制得：5％石斛提取物、3％还原性谷胱甘肽、6％胡萝卜素、2％蓝莓提取物、4％葡萄籽提取物、1％乙酰半胱氨酸、1％维生素E、1％维生素C、0.5％锌、38％葵花籽油；剩余为水。
4.根据权利要求1所述的预防白内障胶囊，其特征在于，按重量百分比计由以下原料制得：6％石斛提取物、3％还原性谷胱甘肽、5％胡萝卜素、4％蓝莓提取物、2％葡萄籽提取物、0.6％乙酰半胱氨酸、1.2％维生素E、1.2％维生素C、0.3％锌、32％葵花籽油；剩余为水。
5.一种权利要求1至4任一项所述的预防白内障胶囊的制备方法，其特征在于，具体过程如下：
S1：将质量百分比的维生素E、维生素C、胡萝卜素、葵花籽油、水进行混合，在50～60℃的条件下搅拌15～20min，得到混合液A；
S2：将质量百分比的石斛提取物、还原性谷胱甘肽、蓝莓提取物、葡萄籽提取物、乙酰半胱氨酸、锌加入至混合液A中，然后在50～60℃的条件下继续搅拌30～60min，得到混合液B；
S3：将混合液B冷却至25～35℃，然后加入至软胶囊制粒机，制成所述预防白内障胶囊。
6.根据权利要求5所述的制备方法，其特征在于，S2中，搅拌的时间为45～50min。
7.根据权利要求5所述的制备方法，其特征在于，S3中，将混合液C冷却至29～31℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010012314.9A CN111000976A (zh) | 2020-01-07 | 2020-01-07 | 一种预防白内障胶囊及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010012314.9A CN111000976A (zh) | 2020-01-07 | 2020-01-07 | 一种预防白内障胶囊及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111000976A true CN111000976A (zh) | 2020-04-14 |
Family
ID=70120448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010012314.9A Pending CN111000976A (zh) | 2020-01-07 | 2020-01-07 | 一种预防白内障胶囊及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000976A (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075116A (en) * | 1989-04-20 | 1991-12-24 | Lahaye Laboratories, Inc. | Composition and method for treatment of macular degeneration |
| CN1778201A (zh) * | 2004-11-18 | 2006-05-31 | 王凯 | 蓝莓果和葡萄籽与决明子等配伍的组合物 |
| US20070082064A1 (en) * | 2005-10-12 | 2007-04-12 | Krawitz Paul L | Nutritional or dietary supplement for the treatment of macular degeneration |
| US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
| CN101152493A (zh) * | 2007-09-17 | 2008-04-02 | 尹克山 | 治疗白内障的中药 |
| CN101897896A (zh) * | 2010-08-04 | 2010-12-01 | 北京科莱博医药开发有限责任公司 | 一种治疗白内障的中药组合物及其药物制剂和制备方法 |
| CN102389412A (zh) * | 2011-11-02 | 2012-03-28 | 广州中医药大学 | 一种治疗白内障的滴眼液 |
| CN103431404A (zh) * | 2013-06-27 | 2013-12-11 | 苟春虎 | 护视明眼胶囊 |
| CN104957618A (zh) * | 2015-07-06 | 2015-10-07 | 广西健宝石斛有限责任公司 | 一种铁皮石斛鱼油护眼胶囊 |
-
2020
- 2020-01-07 CN CN202010012314.9A patent/CN111000976A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075116A (en) * | 1989-04-20 | 1991-12-24 | Lahaye Laboratories, Inc. | Composition and method for treatment of macular degeneration |
| CN1778201A (zh) * | 2004-11-18 | 2006-05-31 | 王凯 | 蓝莓果和葡萄籽与决明子等配伍的组合物 |
| US20070082064A1 (en) * | 2005-10-12 | 2007-04-12 | Krawitz Paul L | Nutritional or dietary supplement for the treatment of macular degeneration |
| US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
| CN101152493A (zh) * | 2007-09-17 | 2008-04-02 | 尹克山 | 治疗白内障的中药 |
| CN101897896A (zh) * | 2010-08-04 | 2010-12-01 | 北京科莱博医药开发有限责任公司 | 一种治疗白内障的中药组合物及其药物制剂和制备方法 |
| CN102389412A (zh) * | 2011-11-02 | 2012-03-28 | 广州中医药大学 | 一种治疗白内障的滴眼液 |
| CN103431404A (zh) * | 2013-06-27 | 2013-12-11 | 苟春虎 | 护视明眼胶囊 |
| CN104957618A (zh) * | 2015-07-06 | 2015-10-07 | 广西健宝石斛有限责任公司 | 一种铁皮石斛鱼油护眼胶囊 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (zh) | 一种复方低浓度阿托品类药物滴眼液及其制备方法 | |
| CN108157568A (zh) | 一种缓解视疲劳的组合糖果及其制备方法和用途 | |
| CN102225087A (zh) | 一种强效护眼的叶黄素复方制剂 | |
| JP6978325B2 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
| CN107412258A (zh) | 一种具有缓解视疲劳功能的保健眼贴 | |
| CN111227097A (zh) | 一种蓝莓叶黄素酯糖果片剂及制备方法 | |
| CN100453086C (zh) | 一种冰珍去翳眼用凝胶制剂及其制备方法 | |
| JP2022531889A (ja) | 人の目の水晶体及び網膜感光細胞栄養素が含まれる、目を保護し視力を良くする生薬菓子 | |
| CN110169484A (zh) | 一种蓝莓叶黄素酯压片糖果及其制备方法 | |
| CN101416741A (zh) | 一种用于缓解视疲劳的保健食品 | |
| CN111202243A (zh) | 强化明目营养软胶囊特殊膳食食品及其制备方法 | |
| CN105520137B (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
| US20200405613A1 (en) | Application of rat tail collagen in field of cosmetics | |
| CN111000976A (zh) | 一种预防白内障胶囊及其制备方法 | |
| CN101785854B (zh) | 叶黄素多维营养保健药物组合物、其制备方法及应用 | |
| CN105106291A (zh) | 能够缓解视疲劳的叶黄素酯软胶囊及制作方法 | |
| CN100415293C (zh) | 生物胶原蛋白口服液及其制备方法 | |
| CN115956670A (zh) | 缓解视疲劳组合物、制剂及制备方法和用途 | |
| CN116139226B (zh) | 一种缓解视疲劳的护眼组合物及其应用 | |
| CN118477122B (zh) | 一种混合酶发酵生产治疗眼疾的中药制剂及其制备方法 | |
| CN109043537A (zh) | 一种提高免疫力的保健食品及其制备方法 | |
| CN115337386B (zh) | 一种护眼组合物及其制备方法 | |
| CN117981855A (zh) | 一种沙棘低聚肽蓝莓粉叶黄素酯的制备方法 | |
| CN101926465A (zh) | 一种叶黄素与多维营养素复方保健品及其制备方法 | |
| CN110974890A (zh) | 一种抗蓝光护眼胶囊及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |
|
| RJ01 | Rejection of invention patent application after publication |